oral regimen
Merck’s HIV Combo Treatment Advances Towards FDA Filing
Doravirine/islatravir (DOR/ISL) combination, Phase 3 trials, Viral suppression, Once-daily oral regimen, FDA submission
Gilead and Merck’s Investigational HIV Combo Shows Promising Long-Term Viral Suppression in Phase 2 Trial
HIV treatment, Weekly oral regimen, Islatravir, Lenacapavir, Viral suppression, Phase 2 clinical trial, Gilead Sciences, Merck & Co.